Standardization of antigen-specific immune therapy.docVIP

 PAGE \* MERGEFORMAT 28 Standardization of antigen-specific immune therapy Keywords: Standardization antigen-specific immune 1 Background Austria, in 1906 Dr. Clemens Von Pirquet concept of allergy made. Patients who are allergic to repeated contact with substances that cause allergic allergic reaction only when there are special and not allergic to normal even if the repeated contact with this substance does not appear allergic reaction to this with a different normal reaction known as the “allergic reaction (allergy)”, which changed the response. 2006 version of GINA and the EAACI and the AAAAI consensus report PRACTALL that children continue to asthma and allergy related to the clinical response of such a change may be manifested as eczema, allergic rhinitis, conjunctivitis and food allergies, an increase of blood eosinophils and total IgE increased. Allergic asthma is a major risk factor, and the relationship between continuity and severity of asthma, which is recommended for all children with allergic asthma, asthma diagnosis to predict prognosis, diagnostic methods, including skin prick test in vivo and in vitro specificity Determination of IgE. Comprehensive asthma prevention and control measures, including avoiding measures, drug therapy, immune therapy, and education. Immunotherapy refers to the allergen immune therapy, although drug therapy is the treatment of choice for asthma, but immunotherapy is currently the only change to the natural course of asthma and there are multiple benefits of treatment, while being focused upon. Immunotherapy was first in 1903 by the German Dunbar began to trial a few years later by the application of the United Kingdom Noon and Freeman allergen-specific immunotherapy (SIT) treatment of hay fever and allergic rhinitis be successful, since the beginning of 1911, a large number of clinical research report. However, over half a century of SIT treatment of asthma in the clinical efficacy and safety